GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vectorite Biomedical Inc (ROCO:4170) » Definitions » Debt-to-Asset

Vectorite Biomedical (ROCO:4170) Debt-to-Asset : 0.00 (As of Dec. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Vectorite Biomedical Debt-to-Asset?

Vectorite Biomedical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was NT$0.00 Mil. Vectorite Biomedical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was NT$0.00 Mil. Vectorite Biomedical's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was NT$412.78 Mil. Vectorite Biomedical's debt to asset for the quarter that ended in Dec. 2024 was 0.00.


Vectorite Biomedical Debt-to-Asset Historical Data

The historical data trend for Vectorite Biomedical's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vectorite Biomedical Debt-to-Asset Chart

Vectorite Biomedical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec21 Dec22 Dec23 Dec24
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 - - - -

Vectorite Biomedical Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Vectorite Biomedical's Debt-to-Asset

For the Biotechnology subindustry, Vectorite Biomedical's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vectorite Biomedical's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vectorite Biomedical's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Vectorite Biomedical's Debt-to-Asset falls into.


;
;

Vectorite Biomedical Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Vectorite Biomedical's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Vectorite Biomedical's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vectorite Biomedical  (ROCO:4170) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Vectorite Biomedical Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Vectorite Biomedical's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Vectorite Biomedical Business Description

Traded in Other Exchanges
N/A
Address
Number 97, Section 1, Xintai 5th Road, 6th Floor, Floor-11, Yuzhi District, New Taipei City, Taipei, TWN, 22175
Vectorite Biomedical Inc is a Taiwan-based biotechnology research and development, cell product (preparation) manufacturing and immune cell collection and storage business.

Vectorite Biomedical Headlines

No Headlines